YBYunpeng Bai

Yunpeng Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yunpeng Bai has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis

    by Ahmed M. Abou-Shanab, Jingmei Yu, Yunpeng Bai, Zhong-Yin Zhang

    The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most frequently inactivated tumor suppressors in human cancers, serving as a critical negative regulator of phosphatidylinositol 3-kinase (PI3K)–AKT signaling. Although genetic mutation or deletion commonly underlie functional PTEN loss, accumulating evidence indicates that post-transcriptional and post-translational mechanisms also substantially contribute to PTEN suppression. Phosphatases of regenerating liver (PRLs), comprising PRL1, PRL2, and PRL3, are oncogenic phosphatases frequently overexpressed in both solid and hematological malignancies. Emerging studies reveal that PRLs can downregulate PTEN through a post-translational mechanism by direct dephosphorylation of PTEN at Tyr336, therefore promoting PTEN ubiquitination and proteasomal degradation. PRLs can also reduce PTEN expression through a post-transcriptional mechanism by dephosphorylating the inhibitory Tyr570 in JAK2, thereby activating the JAK2/STAT3-mediated miR-21 expression. These coordinated actions collectively amplify PI3K–AKT signaling, consequently promoting proliferation, survival, and metastasis. In the present review, we synthesize current knowledge of PRL structure, evolution, and functional diversity, evaluate genetic, biochemical, and organismal evidence linking PRLs to PTEN regulation, and discuss insights on PRL oncogenicity derived from experimental models. We further examine context-dependent functions of PRLs, unresolved questions regarding catalytic versus scaffold activities, and the therapeutic potential of targeting the PRL–PTEN axis. Understanding how PRLs modulate PTEN activity may reveal new strategies to restore tumor suppressor function in PTEN-deficient cancers.

  • Open Access

    Protein tyrosine phosphatase inactivation by electrophilic tyrosine modification

    by Madeleine L. Ware, David M. Leace, Zihan Qu, Quentin Schaefer, Sagar D. Vaidya, Mikayla L. Horvath, Zhihong Li, Yunpeng Bai, Zhong-Yin Zhang, Ku-Lung Hsu

    Here, we develop covalent inhibitors that inactivate protein tyrosine phosphatases (PTPs) via electrophilic modification of functional tyrosines.


  • Open Access

    The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor

    by Qinglin Li, Yunpeng Bai, Sarah M. Cavender, Yiming Miao, Frederick Nguele Meke, Emily L. Lasse-Opsahl, Peipei Zhu, Gina M. Doody, W. Andy Tao, Zhong-Yin Zhang

    The phosphatases of regenerating liver (PRLs) are members of the protein tyrosine phosphatase (PTP) superfamily that play pro-oncogenic roles in cell proliferation, migration, and survival. We previously demonstrated that PRLs can post-translationally down-regulate PTEN, a tumor suppressor frequently inactivated in human cancers, by dephosphorylating PTEN at Tyr336, which promotes the NEDD4-mediated PTEN ubiquitination and proteasomal degradation. Here, we report that PRLs can also reduce PTEN expression by up-regulating microRNA-21 (miR-21), which is one of the most frequently overexpressed miRNAs in solid tumors. We observe a broad correlation between PRL and miR-21 levels in multiple human cancers. Mechanistically, PRL2, the most abundant and ubiquitously expressed PRL family member, promotes the JAK2/STAT3 pathway-mediated miR-21 expression by directly dephosphorylating JAK2 at Tyr570. Finally, we confirm that the PRL2-mediated miR-21 expression contributes to its oncogenic potential in breast cancer cells. Our study defines a new functional role of PRL2 in PTEN regulation through a miR-21-dependent post-transcriptional mechanism, in addition to our previously reported NEDD4-dependent post-translational PTEN regulation. Together, these studies further establish the PRLs as negative regulators of PTEN.


  • Valosin-Containing Protein (VCP)/p97 Oligomerization

    by Guimei Yu, Yunpeng Bai, Zhong-Yin Zhang

    Valosin-containing protein (VCP), also known as p97, is an evolutionarily conserved AAA+ ATPase essential for cellular homeostasis. Cooperating with different sets of cofactors, VCP is involved in multiple cellular processes through either the ubiquitin-proteasome system (UPS) or the autophagy/lysosomal route. Pathogenic mutations frequently found at the interface between the NTD domain and D1 ATPase domain have been shown to cause malfunction of VCP, leading to degenerative disorders including the inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis (ALS), and cancers. Therefore, VCP has been considered as a potential therapeutic target for neurodegeneration and cancer. Most of previous studies found VCP predominantly exists and functions as a hexamer, which unfolds and extracts ubiquitinated substrates from protein complexes for degradation. However, recent studies have characterized a new VCP dodecameric state and revealed a controlling mechanism of VCP oligomeric states mediated by the D2 domain nucleotide occupancy. Here, we summarize our recent knowledge on VCP oligomerization, regulation, and potential implications of VCP in cellular function and pathogenic progression.


  • Open Access

    Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers

    by Yiming Miao, Yunpeng Bai, Jinmin Miao, Allison A. Murray, Jianping Lin, Jiajun Dong, Zihan Qu, Ruo-Yu Zhang, Quyen D. Nguyen, Shaomeng Wang, et al.

    Aberrant activation of RAS/MAPK signaling is common in cancer, and efforts to inhibit pathway components have yielded drugs with promising clinical activities. Unfortunately, treatment-provoked adaptive resistance mechanisms inevitably develop, limiting their therapeutic potential. As a central node essential for receptor tyrosine kinase–mediated RAS activation, SHP2 has emerged as an attractive cancer target. Consequently, many SHP2 allosteric inhibitors are now in clinical testing. Here we discovered a previously unrecognized off-target effect associated with SHP2 allosteric inhibitors. We found that these inhibitors accumulate in the lysosome and block autophagic flux in an SHP2-independent manner. We showed that off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity. We also demonstrated that SHP2 allosteric inhibitors harboring this off-target activity not only suppress oncogenic RAS signaling but also overcome drug resistance such as MAPK rebound and protective autophagy in response to RAS/MAPK pathway blockage. Finally, we exemplified a therapeutic framework that harnesses both the on- and off-target activities of SHP2 allosteric inhibitors for improved treatment of mutant RAS–driven and drug-resistant malignancies such as pancreatic and colorectal cancers.


  • Open Access

    Figure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice

  • Open Access

    FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Open Access

    FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion inhibits tumor cell proliferations

  • Open Access

    FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models

    by Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang

    Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.